Achieve Life Sciences (NASDAQ:ACHV) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Achieve Life Sciences (NASDAQ:ACHV) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

ACHV has been the subject of several other research reports. Rodman & Renshaw assumed coverage on Achieve Life Sciences in a research note on Thursday. They set a “buy” rating and a $12.00 price target for the company. Oppenheimer restated an “outperform” rating and set a $11.00 target price on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Finally, Raymond James began coverage on shares of Achieve Life Sciences in a report on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $14.80.

Achieve Life Sciences Trading Down 3.2 %

Shares of Achieve Life Sciences stock opened at $4.25 on Thursday. The company has a 50-day moving average of $4.72 and a two-hundred day moving average of $4.77. Achieve Life Sciences has a 12-month low of $3.03 and a 12-month high of $5.98. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The stock has a market cap of $146.16 million, a PE ratio of -3.76 and a beta of 1.57.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same quarter in the previous year, the firm earned ($0.34) earnings per share. On average, research analysts anticipate that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Achieve Life Sciences

A number of institutional investors have recently modified their holdings of ACHV. Propel Bio Management LLC purchased a new stake in shares of Achieve Life Sciences in the first quarter valued at $11,149,000. Vanguard Group Inc. increased its stake in shares of Achieve Life Sciences by 56.6% during the 1st quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company’s stock valued at $4,311,000 after acquiring an additional 342,731 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock valued at $3,552,000 after acquiring an additional 48,474 shares during the last quarter. State Street Corp lifted its holdings in shares of Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock worth $2,045,000 after acquiring an additional 27,419 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Achieve Life Sciences in the second quarter worth approximately $482,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.